Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | TYR | P14679 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552373 | 0.91 | TSHR (0.57) | HSD17B2TSHRBLMNPSR1CYP3A4 | |
| SCHEMBL17179845 | 0.90 | HSD17B2 (0.54) | HSD17B2TSHRBLMNPSR1CYP3A4 | |
| SCHEMBL11582477 | 0.88 | CA12 (0.52) | ACHEGAAMEN1ALDH1A1MAPT | |
| SCHEMBL490843 | 0.85 | HSD17B2 (0.57) | HSD17B2TSHRBLMNPSR1CYP3A4 | |
| SCHEMBL298386 | 0.84 | TSHR (0.67) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL16231326 | 0.84 | HSD17B2 (0.56) | HSD17B2TSHRBLMNPSR1CYP3A4 | |
| SCHEMBL16868808 | 0.82 | TSHR (0.52) | HSD17B2TSHRBLMNPSR1CYP3A4 | |
| Alcohol SCHEMBL17179872 | 0.82 | TSHR (0.63) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL29396091 | 0.80 | ALDH1A1 (0.54) | HSD17B2TSHRBLMNPSR1NFKB1 | |
| SCHEMBL8588723 | 0.80 | GAA (0.48) | HSD17B2TSHRBLMNPSR1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-2932858-A1 | Homovanillic acid esters, in particular for achieving an impression of heat and/or spiciness | Symrise AG (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-9073898-B2 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130245036-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
| EP-1577290-A1 | AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230457-A1 | Substituted Isoquinolinones and Quinazolinones | MDM4, MDM2, TP53 | HSD17B2 1765/4885TSHR 3334/4885BLM 518/4885 |
| US-20130245036-A1 | CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION | MDM4, TP53, TP53BP1 | HSD17B2 2999/4885TSHR 4124/4885BLM 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.